BioGaia AB (publ) (BIOG-B.ST)
BioGaia AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Stockholm, AB, SE. The stock last traded at $115.80, up 1.58% on the session, giving a market capitalisation of $11.41B. Its beta of 0.32 implies it has historically moved less than the broad market.
BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The company operates through three primary divisions. Its Pediatrics segment offers various items such as drops, oral rehydration solutions, and gut health tablets, in addition to supplying cultures for integration into infant formula. The Adult Health segment provides gut health tablets and oral health lozenges, alongside furnishing cultures to licensees for use in dairy products. A third segment, "Other," specializes in packaging solutions. BioGaia's extensive product portfolio targets a range of health issues, including infantile colic and digestive health in children, antibiotic-associated and acute diarrhea, gingivitis, periodontal disease, general well-being, Helicobacter pylori bacterial infections (linked to gastric ulcers), and concerns related to low bone density. All of its offerings are sold exclusively under the BioGaia brand.
BioGaia AB (publ) is most often compared with the following Healthcare names: